Sugi Predict

Sugi Predict / Compounds / SCHEMBL153254

SCHEMBL153254

SCHEMBL153254

CC(N)Cc1c[nH]c(=O)[nH]c1=O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ADRB1 P08588 1/20 0.45
▸ HTR1A P08908 1/20 0.45
▸ ADRA2A P08913 1/20 0.45
▸ SLC6A2 P23975 1/20 0.45
▸ HTR1D P28221 1/20 0.45
▸ HTR1B P28222 1/20 0.45
▸ HTR2A P28223 1/20 0.45
▸ HTR2C P28335 1/20 0.45
▸ HTR1E P28566 1/20 0.45
▸ SLC6A4 P31645 1/20 0.45
▸ HTR7 P34969 1/20 0.45
▸ HTR2B P41595 1/20 0.45
▸ HTR6 P50406 1/20 0.45
▸ SLC6A3 Q01959 1/20 0.45
▸ ATAD2 Q6PL18 1/20 0.44
▸ SOS2 Q07890 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Uracil SCHEMBL28379047 0.88 CRBN (0.49) ADRB1HTR1AADRA2ASLC6A2HTR1D
SCHEMBL7133034 0.85 ATAD2 (0.47) ATAD2
SCHEMBL7598099 0.82 ATAD2 (0.41) ATAD2
SCHEMBL27627581 0.79 ATAD2 (0.41) ATAD2
SCHEMBL28686231 0.77 MAPT (0.51) HTR1AHTR2AHTR2CSLC6A4HTR7
SCHEMBL4273433 0.77 DPYD (0.31) —
SCHEMBL4273436 0.77 ADORA2B (0.34) —
SCHEMBL161148 0.76 ATAD2 (0.54) ATAD2
SCHEMBL19131291 0.75 ATAD2 (0.38) ATAD2
SCHEMBL7131308 0.74 HCAR3 (0.48) ATAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170246200-A1 MICRORNA-132/212 FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS UNIVERSITé LAVAL (CA) 2017-08-31 — — US claimed
US-9725474-B2 Modified nucleic acid TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-08 — — US claimed
WO-2016044929-A1 MICRORNA-132/212 FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS UNIVERSITé LAVAL (CA) 2016-03-31 — — WO claimed
WO-2013071079-A1 LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-05-16 — — WO claimed
EP-4748381-A2 PRODUCTS AND COMPOSITIONS Silence Therapeutics GmbH (DE) 2026-05-27 — — EP disclosed
EP-4748382-A2 PRODUCTS AND COMPOSITIONS Silence Therapeutics GmbH (DE) 2026-05-27 — — EP disclosed
CN-122095091-A DsRNA for inhibiting LPA gene expression and application thereof — 2026-05-26 — — CN disclosed
CN-122095092-A Inhibitor for inhibiting inhibin Beta E gene expression and application thereof — 2026-05-26 — — CN disclosed
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS BRISTOL MYERS SQUIBB CO (US) 2026-05-21 — — US disclosed
WO-2026106956-A1 DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN MERCK SHARP & DOHME LLC (US) 2026-05-21 — — WO disclosed
US-12629412-B2 Betacoronavirus mRNA vaccines MODERNATX, INC. (US) 2026-05-19 — — US disclosed
WO-2026098737-A1 NUCLEIC ACID CONJUGATE AND PHARMACEUTICAL COMPOSITION FOR LIPID DELIVERY, AND USE THEREOF 苏州时安生物技术有限公司 2026-05-15 — — WO disclosed
US-20050107325-A1 Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs ALNYLAM PHARMACEUTICALS, INC. 2005-05-19 — — US disclosed
WO-2005004794-A2 METHOD OF TREATING NEURODEGENERATIVE DISEASE ALNYLAM PHARMACEUTICALS INC. (US) 2005-01-20 — — WO disclosed
WO-2004094595-A2 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS INC. (US) 2004-11-04 — — WO disclosed
WO-2004094345-A2 PROTECTED MONOMERS ALNYLAM PHARMACEUTICALS INC. (US) 2004-11-04 — — WO disclosed
WO-2004091515-A2 iRNA CONJUGATES ALNYLAM PHARMACEUTICALS, INC. (US) 2004-10-28 — — WO disclosed
WO-2004090108-A2 IRNA CONJUGATES ALNYLAM PHARMACEUTICALS (US) 2004-10-21 — — WO disclosed
WO-2004080406-A2 THERAPEUTIC COMPOSITIONS ALNYLAM PHARMACEUTICALS (US) 2004-09-23 — — WO disclosed
WO-2004064737-A2 THERAPEUTICS COMPOSITIONS ALNYLAM PHARMACEUTICALS (US) 2004-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170246200-A1 MICRORNA-132/212 FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS TARDBP, RBM12, HTT ADRB1 4561/4885HTR1A 1589/4885ADRA2A 4168/4885
US-20260138999-A1 REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS RNGTT, CDA, DCTD ADRB1 2178/4885HTR1A 3671/4885ADRA2A 2744/4885
US-12629412-B2 Betacoronavirus mRNA vaccines RNMT, RNGTT, METTL16 ADRB1 2179/4885HTR1A 3378/4885ADRA2A 2674/4885
US-20050107325-A1 Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs LDLR, SLC29A1, SLC29A2 ADRB1 2323/4885HTR1A 2320/4885ADRA2A 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.